• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Talaporfin sodium.
【24h】

Talaporfin sodium.

机译：Talaporfin钠。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IMPORTANCE OF THE FIELD: Despite therapeutic advances, cancer remains the cause of an estimated 23% of deaths in the USA. New treatments for malignancy are greatly needed. AREAS COVERED IN THIS REVIEW: Talaporfin sodium is a light-activated drug that causes tissue death through induction of apoptosis. Systemic antitumor effects mediated by CD8(+) T cells have been demonstrated in preclinical studies, providing a mechanism for distant response of tumors noted in clinical trials. Talaporfin sodium is approved in Japan for early-stage endobronchial cancer. Phase I and II studies in solid tumors have shown tumor regression in patients refractory to other therapies. Phase III pivotal studies against hepatocellular carcinoma as monotherapy and liver-metastatic colorectal cancer in combination with chemotherapy are ongoing. Talaporfin sodium is also in studies in men with symptomatic benign prostatic hyperplasia. Substantial safety data from clinical trials so far indicate that the drug is well tolerated. WHAT THE READER WILL GAIN: Talaporfin sodium has a broad safety profile and a mode of action that could affect growth in treated and untreated tumors. TAKE HOME MESSAGE: Clinical and preclinical studies indicate that talaporfin sodium treatment may offer a powerful option to synergize current therapies, as well as an alternative monotherapy in treating cancer.
机译：该领域的重要性：尽管治疗性进展，癌症仍然是估计在美国死亡人数的原因。非常需要对恶性肿瘤进行新的治疗方法。本报告所涵盖的地区：Talaporfin钠是一种光活性药物，通过诱导细胞凋亡来导致组织死亡。已在临床前研究中证明由CD8（+）T细胞介导的全身抗肿瘤作用，为临床试验中注意的肿瘤的远处反应提供了一种机制。在日本批准了Talaporfin钠，用于早期的内核癌症。固体瘤中的II和II研究表明患者对其他疗法难治的肿瘤消退。持续与化疗结合化疗的肝细胞癌作为单疗法和肝转移性结直肠癌的III期枢转研究。 Talaporfin钠也在具有症状性良性前列腺增生的男性的研究中。迄今为止，临床试验的大量安全数据表明该药物耐受良好。读者将获得什么：Talaporfin钠具有广泛的安全性曲线和可能影响治疗和未经处理的肿瘤生长的作用方式。带回家消息：临床和临床前研究表明，Talaporfin钠治疗可能提供强大的选择来协同当前疗法，以及治疗癌症的替代单一疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号